(Q37095310)

English

Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer

scientific article published on 13 September 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer (English)

1 reference

Europe PubMed Central

18 August 2017

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

decision making

1 reference

based on heuristic

inferred from title

1

object named as

Shelby D Reed

1 reference

Europe PubMed Central

18 August 2017

author name string

Michaela A Dinan

2

1 reference

Europe PubMed Central

18 August 2017

Kevin A Schulman

3

1 reference

Europe PubMed Central

18 August 2017

Gary H Lyman

4

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

13 September 2012

1 reference

Europe PubMed Central

18 August 2017

Genetics in Medicine

1 reference

Europe PubMed Central

18 August 2017

15

1 reference

Europe PubMed Central

18 August 2017

3

1 reference

Europe PubMed Central

18 August 2017

203-211

1 reference

Europe PubMed Central

18 August 2017

https://scigraph.springernature.com/pub.10.1038/gim.2012.119

0 references

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Factors influencing treatment recommendations in node-negative breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Health-state utility values in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Impact of gene expression profiling tests on breast cancer outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Patient time costs associated with cancer care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Can differences in breast cancer utilities explain disparities in breast cancer care?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Work absence after breast cancer diagnosis: a population-based study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

29 September 2017

US insurance program's experience with a multigene assay for early-stage breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

3 September 2018

The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

3 September 2018

The influence of a gene expression profile on breast cancer decisions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

3 September 2018

Health related quality of life in different states of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

3 September 2018

The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

3 September 2018

Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

3 September 2018

Economic outcomes of breast cancer survivorship: CALGB study 79804.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3743447

3 September 2018

Breast cancer multidisciplinary team adjuvant therapy decision making and adjuvant! Online

1 reference

https://pubmed.ncbi.nlm.nih.gov/22975761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22975761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22975761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization

1 reference

https://pubmed.ncbi.nlm.nih.gov/22975761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22975761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report

1 reference

https://pubmed.ncbi.nlm.nih.gov/22975761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/GIM.2012.119

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37095310&oldid=1756665001"